ASX Blue Chip Shares of CSL and PME Creating a Buying Opportunity
A major new contract win has lifted Pro Medicus’s share price while CSL’s renewed buyback strategy is unlocking value at the right time which leaves both companies well placed heading into the next phase of growth.
Pro Medicus Limited (ASX: PME)
saw a jump in its share price after the company announced another major contract win in the US market that expands its footprint in health imaging.
The company signed a five-year $44 million contract with Advanced Radiology Management which is a major private radiology reading group in the United States.
This new deal is based on PME’s transaction-based model which means the contract has further upside potential as imaging volumes increase over time.
The agreement will see the company’s cloud-based Visage 7 Enterprise Imaging Platform rolled out across the group which includes the ultra-fast Visage 7 Viewer that has become PME’s biggest global growth driver.
PME said that Advanced Radiology Management chose Visage 7 because it provides a single, unified platform for all diagnostic interpretation and can be deployed fully in the cloud which is rapidly becoming the standard in North America.
Implementation work will begin immediately with the system expected to go live in late Q2 of calendar year 2026.
CSL Limited (ASX: CSL)
looks like its heading into a fresh phase of momentum as its plasma, vaccine and kidney-care businesses keep expanding.
Revenue for FY2025 was around US$15.56 billion which is about a 5% growth from last year, supported by steady gains across CSL Behring, CSL Seqirus and CSL Vifor.
Net profit after tax that belongs to shareholders was up 17% to US$3.09 billion helped mainly by better margins.
Free cash flow jumped 58% to US$2.86 billion because of lower capex and tighter cost control right across the group.
The company has also confirmed a long multi-year on-market share buyback starting with $750 million in FY2026 and this amount is expected to slowly increase over the medium term.
After the recent correction in the share price, the company has been quite active buying back its own stock which makes the outlook even better.
FY26 guidance is about 4–5% revenue growth and 7–10% NPATA growth excluding restructuring cost which is really impressive.
(Source: Company Reports)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
